Ads
related to: mrns stock
Search results
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] Sees Increase in Stock Value – Knox Daily
Knox Daily· 6 days agoEarlier on January 20, 2023, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for MRNS stock. Analyzing MRNS< ...
How To Know If Marinus Pharmaceuticals Inc
Marketing Sentinel· 6 days agoCompany’s recent per share price level of $1.30 trading at $0.01 or 0.78% at ring of the bell on the day assigns it a market valuation of $71.41M. That closing price of MRNS
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Zacks via Yahoo Finance· 15 hours agoData from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes...
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Zacks via Yahoo Finance· 16 hours agoCorcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating...
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
Zacks via Yahoo Finance· 2 days agoMirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion...
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
Zacks via Yahoo Finance· 3 days agoThe FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for...
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Zacks· 6 days agoSales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
Zacks· 6 days agoCandel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.